Bimagrumab 3rd Novartis drug to win FDA 'breakthrough' designation
This article was originally published in Scrip
Executive Summary
Novartis has won its third breakthrough therapy designation from the US FDA, which granted the status to the Swiss drug maker's investigational muscle-wasting disease drug bimagrumab (BYM338), a fully human monoclonal antibody.